BIIB Biogen Inc. - Common Stock
$218,21
Preço · Ago 19, 2026
Fundamentais a partir de Jul 29, 2026
Intervalo 52 Semanas
$132–$220
98% of range
Classificação do Analista
BUY
43 analysts
Preço-Alvo
$236
+8% upside
P/E (TTM)
29.0
ROE
7.2%
Margem de Lucro Líquido
13.1%
Sobre Biogen Inc. - Common Stock Visão geral da empresa da Wikipedia
Biogen é uma empresa de biotecnologia americana, sediada em Cambridge, Massachusetts, especializada na descoberta, desenvolvimento e distribuição de terapias para o tratamento de transtorno neurológico para pacientes em todo o mundo; tratando principalmente da doença de Alzheimer, esclerose múltipla, imunologia e hematologia. Na Alemanha, a Biogen vende uma preparação para o tratamento da psoríase.
Ler mais
Biogen (anteriormente Biogen Idec) é uma empresa de biotecnologia americana, sediada em Cambridge, Massachusetts, especializada na descoberta, desenvolvimento e distribuição de terapias para o tratamento de transtorno neurológico para pacientes em todo o mundo; tratando principalmente da doença de Alzheimer, esclerose múltipla, imunologia e hematologia. Na Alemanha, a Biogen vende uma preparação para o tratamento da psoríase.
A empresa também possui escritórios na Austrália, Europa, Japão e Canadá. A sede internacional para mercados fora dos Estados Unidos fica em Zug, na Suíça.
O grupo utiliza a tecnologia de ADN recombinante (rDNA), isso torna possível produzir proteínas humanas e, portanto, medicamentos com a ajuda de micro-organismos. A empresa continua desenvolvendo novas substâncias e moléculas já aprovadas.
== Referências ==
Fonte: Wikipedia, CC BY-SA 4.0 · Ver na Wikipedia ↗
BIIB Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$218.21
Capitalização de Mercado
$37.40B
P/E (TTM)
29.0
EPS (TTM)
$8.79
Receita (TTM)
$9.89B
Rendimento div.
—
ROE
7.2%
Dívida/Capital
—
Intervalo 52 Semanas
$132 – $220
BIIB Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$9.89B
2016-12-31
→
2025-12-31
EPS
$8.79
2016-12-31
→
2025-12-31
Fluxo de caixa livre
$2.05B
2016-12-31
→
2025-12-31
Margens
13.1%
2016-12-31
→
2020-12-31
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
BIIB
Mediana de Pares
P/E (TTM)
29.0
17.7
P/S (TTM)
3.8
6.8
P/B
2.0
6.4
Price / FCF (Preço / FCF)
18.2
—
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
BIIB
Mediana de Pares
Net Profit Margin (Margem de Lucro Líquido)
13.1%
20.3%
ROA
4.5%
11.4%
ROE
7.2%
16.8%
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
BIIB
Mediana de Pares
Current Ratio (Índice de liquidez corrente)
2.7
3.4
Quick Ratio (Índice de Liquidez Seca)
0.4
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
BIIB
Mediana de Pares
Revenue YoY (Receita Ano a Ano)
2.2%
—
Revenue CAGR 3Y (CAGR Receita 3A)
-0.94%
—
Revenue CAGR 5Y (CAGR Receita 5A)
-6.0%
—
EPS YoY
-21.4%
—
Net Income YoY (Lucro Líquido Ano a Ano)
-20.8%
—
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
BIIB
Mediana de Pares
BIIB Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
43 analistas
- Compra forte 9 20,9%
- Compra 20 46,5%
- Manter 13 30,2%
- Venda 1 2,3%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
31 analistas · 2026-08-13
Mediana
$237.00
Agora
$218.21
Mín
$165.00
Máx
$300.00
Alvo mediano
$237.00
+8,6%
Alvo médio
$235.57
+8,0%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.75%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $3.60 | $3.01 | 0.59% |
| 31 de Março de 2026 | $3.57 | $2.83 | 0.74% |
| 31 de Dezembro de 2025 | $1.99 | $1.65 | 0.34% |
| 30 de Setembro de 2025 | $4.81 | $3.96 | 0.85% |
| 30 de Junho de 2025 | $5.47 | $3.94 | 1.5% |
| 31 de Março de 2025 | $3.02 | $2.58 | 0.44% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Cost of Revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | |
| Gross Profit | · | · | · | · | · | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | |
| SG&A Expense | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | |
| Operating Expenses | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.40B | $7.34B | $7.56B | $6.93B | $6.30B | $5.87B | $5.75B | |
| Operating Income | · | · | · | · | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | |
| Interest Expense | $268M | $250M | $247M | $247M | $254M | $222M | $187M | $201M | $251M | $260M | $96M | $30M | |
| Interest Income | $125M | $68M | $276M | $89M | $11M | $42M | $120M | $112M | $78M | $63M | $22M | $12M | |
| Other Non-op | $-25M | $3M | $-400.0K | $10M | $6M | $-3M | $-47M | $-10M | $-15M | $-18M | $-14M | $-26M | |
| Pretax Income | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B | $5.90B | $5.13B | $4.93B | $4.77B | $3.95B | |
| Income Tax | $264M | $274M | $135M | $633M | $52M | $992M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $990M | |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| EPS (Basic) | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | |
| EPS (Diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | |
| Shares (Basic) | 146,500,000 | 145,600,000 | 144,700,000 | 145,300,000 | 149,100,000 | 160,900,000 | 187,100,000 | 204,900,000 | 212,600,000 | 218,400,000 | 230,700,000 | 236,400,000 | |
| Shares (Diluted) | 147,100,000 | 145,900,000 | 145,600,000 | 146,000,000 | 149,600,000 | 161,300,000 | 187,400,000 | 205,300,000 | 213,000,000 | 218,800,000 | 231,200,000 | 237,200,000 | |
| EBITDA | $780M | $673M | $495M | $518M | $3.33B | $5.01B | $7.72B | $6.91B | $6.43B | $5.83B | $5.49B | $4.66B |
Balanço Patrimonial 29
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | · | · | · | · | · | $2.91B | $1.22B | $1.57B | $2.33B | $1.31B | $1.20B | |
| Short-term Investments | · | · | · | · | · | · | $1.56B | $2.31B | $2.12B | $2.57B | $2.12B | $640M | |
| Receivables | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B | $1.91B | $1.88B | $1.96B | $1.79B | $1.44B | $1.23B | $1.29B | |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B | $1.07B | $804M | $930M | $903M | $1.00B | $893M | $804M | |
| Other Current Assets | $1.12B | $752M | $1.18B | $1.42B | $741M | $881M | $631M | $688M | $962M | $1.09B | $837M | $310M | |
| Current Assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B | $8.38B | $7.64B | $7.87B | $8.73B | $6.70B | $4.54B | |
| PP&E (Net) | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B | $3.41B | $3.25B | $3.60B | $3.18B | $2.50B | $2.19B | $1.77B | |
| PP&E (Gross) | $5.99B | $5.85B | $5.71B | $5.46B | $5.42B | $5.19B | $4.84B | $5.40B | $4.74B | $3.94B | $3.52B | $2.95B | |
| Accum. Depreciation | $2.90B | $2.67B | $2.40B | $2.17B | $2.01B | $1.78B | $1.59B | $1.80B | $1.56B | $1.44B | $1.33B | $1.19B | |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B | $5.76B | $5.76B | $5.71B | $4.63B | $3.67B | $2.66B | $1.76B | |
| Intangibles | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B | $3.08B | $3.53B | $3.12B | $3.88B | $3.81B | $4.09B | $4.03B | |
| Other Non-current Assets | $751M | $560M | $745M | $1.53B | $1.94B | $2.90B | $1.25B | $1.69B | $432M | $1.34B | $1.11B | $755M | |
| Total Assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Accounts Payable | $432M | $424M | $403M | $492M | $589M | $455M | $531M | $370M | $396M | $280M | $267M | $229M | |
| Short-term Debt | · | $1.75B | $150M | $0 | $999M | $0 | $1.50B | $0 | · | · | · | · | |
| Current Liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B | $3.74B | $4.86B | $3.30B | $3.37B | $3.42B | $2.58B | $2.22B | |
| Capital Leases | $290M | $334M | $400M | $333M | $330M | $402M | $413M | $0 | · | · | · | · | |
| Deferred Tax | $508M | $190M | $642M | $335M | $694M | $1.03B | $2.81B | $1.64B | $123M | $93M | $125M | $52M | |
| Other Non-current Liabilities | $748M | $732M | $781M | $944M | $1.32B | $1.33B | $1.35B | $1.39B | $1.63B | $722M | $906M | $650M | |
| Total Liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B | $13.90B | $12.26B | $11.05B | $10.75B | $10.13B | $3.50B | |
| Long-term Debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B | $7.43B | $4.46B | $5.94B | $5.93B | $6.51B | $6.52B | $580M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |
| Paid-in Capital | $863M | $569M | $302M | $73M | $68M | $0 | $0 | $0 | $98M | $0 | $0 | $4.20B | |
| Retained Earnings | $20.55B | $19.26B | $17.63B | $16.47B | $13.91B | $13.98B | $16.46B | $16.26B | $15.81B | $15.07B | $12.21B | $9.28B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.61B | $2.61B | $2.61B | |
| AOCI | $-182M | $-136M | $-154M | $-165M | $-107M | $-299M | $-135M | $-240M | $-318M | $-320M | $-224M | $-60M | |
| Stockholders' Equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B | $10.70B | $13.34B | $13.04B | $12.61B | $12.14B | $9.37B | $10.81B | |
| Liabilities + Equity | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Shares Outstanding | 170,500,000 | 169,500,000 | 144,900,000 | 167,900,000 | 170,800,000 | 176,200,000 | 174,200,000 | 197,200,000 | 211,500,000 | 215,900,000 | 218,600,000 | 234,600,000 |
Fluxo de Caixa 18
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $780M | $673M | $495M | $518M | $488M | $457M | $465M | $650M | $1.08B | $683M | $600M | $688M | |
| Stock-based Comp | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M | $161M | $155M | |
| Deferred Tax | $362M | $-158M | $-306M | $-169M | $-427M | $149M | $67M | $108M | $92M | $-175M | $-146M | $-308M | |
| Amort. of Intangibles | $507M | $386M | $241M | $246M | $252M | $255M | $274M | $381M | $455M | $373M | $383M | $490M | |
| Restructuring | $49M | $30M | $219M | $131M | $0 | $0 | $2M | $12M | $900.0K | $33M | $93M | $0 | |
| Other Non-cash | $-521M | $437M | $-67M | $-2.27B | $1.78B | $-575M | $260M | $475M | $711M | $157M | $-447M | $-528M | |
| Operating Cash Flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B | $3.92B | $2.94B | |
| CapEx | $154M | $154M | $277M | $240M | $258M | $425M | $514M | $771M | $867M | $616M | $643M | $288M | |
| Investing Cash Flow | $-1.37B | $-799M | $-4.10B | $1.58B | $-564M | $-609M | $470M | $-2.05B | $-2.96B | $-2.48B | $-4.55B | $-1.54B | |
| Debt Issued | $1.73B | $0 | $997M | $0 | $0 | $2.97B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | $-17M | $0 | $997M | $0 | $0 | $2.97B | · | · | · | · | · | · | |
| Stock Repurchased | · | $0 | $0 | $750M | $1.80B | $6.68B | $5.87B | $4.35B | $1.37B | $1.00B | $5.00B | $887M | |
| Net Stock Activity | · | $0 | $0 | $-750M | $-1.80B | $-6.68B | $-5.87B | $-4.35B | $-1.37B | $-1.00B | $-5.00B | $-887M | |
| Financing Cash Flow | $-302M | $-684M | $149M | $-1.75B | $-2.09B | $-5.27B | $-5.86B | $-4.47B | $-2.38B | $-1.05B | $783M | $-756M | |
| Net Change in Cash | · | · | · | · | · | · | · | · | $-792M | $1.05B | $149M | $643M | |
| Taxes Paid | $864M | $355M | $741M | $933M | $248M | $907M | $1.06B | $1.01B | $1.07B | $1.64B | $1.67B | $1.16B | |
| Free Cash Flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B | $3.81B | $6.56B | $5.42B | $3.68B | $3.91B | $3.07B | $2.65B | |
| Levered FCF | $1.83B | $2.51B | $1.05B | $941M | $3.14B | $3.63B | $6.41B | $5.26B | $3.55B | $3.71B | $3.00B | $2.63B |
Lucratividade 8
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% | 88.5% | 87.9% | |
| Operating Margin | · | · | · | · | 25.9% | 33.8% | 49.0% | 43.8% | 43.5% | 45.0% | 45.4% | 40.9% | |
| Net Margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% | |
| Pretax Margin | 15.7% | 19.7% | 13.2% | 35.3% | 15.9% | 37.5% | 49.6% | 43.9% | 41.8% | 43.1% | 44.3% | 40.7% | |
| EBITDA Margin | 7.9% | 7.0% | 5.0% | 5.1% | 30.3% | 37.2% | 53.7% | 51.3% | 52.3% | 50.9% | 51.0% | 48.0% | |
| ROA | 4.5% | 5.9% | 4.5% | 12.6% | 6.4% | 15.4% | 22.4% | 18.1% | 10.9% | 17.5% | 21.0% | 22.4% | |
| ROE | 7.2% | 9.9% | 7.9% | 25.0% | 14.4% | 33.3% | 44.8% | 33.1% | 20.5% | 34.4% | 35.1% | 30.2% | |
| ROIC | · | · | · | · | 25.3% | 34.2% | 44.2% | 34.2% | 22.1% | 31.8% | 39.5% | 27.5% |
Liquidez e Solvência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 | 1.8 | 1.7 | 2.3 | 2.3 | 2.6 | 2.6 | 2.1 | |
| Quick Ratio | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 | 0.5 | 1.3 | 1.7 | 1.6 | 1.9 | 1.8 | 1.4 | |
| Interest Coverage | · | · | · | · | 11.2 | 20.4 | 37.6 | 29.4 | 21.3 | 19.8 | 51.2 | 134.7 |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | |
| Inventory Turnover | 1.0 | 0.9 | 1.3 | 1.7 | 1.7 | 1.9 | 2.3 | 2.0 | 1.7 | 1.6 | 1.5 | 1.6 | |
| Receivables Turnover | 7.2 | 6.3 | 5.8 | 6.3 | 6.3 | 7.1 | 7.5 | 7.2 | 7.6 | 8.6 | 8.5 | 9.2 |
Taxas de Crescimento 9
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.94% | -4.1% | -9.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -6.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -21.4% | 40.3% | -61.8% | 100.7% | -58.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -25.0% | 2.4% | -31.5% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -18.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -20.8% | 40.6% | -61.9% | 95.8% | -61.1% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | 1.6% | -33.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -20.2% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Net Income TTM | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| Market Cap | $25.84B | $22.30B | $37.50B | $39.88B | $35.27B | $37.32B | $51.69B | $59.34B | $67.38B | $61.22B | $66.97B | $79.62B | |
| P/E | 20.0 | 13.7 | 32.5 | 13.3 | 23.1 | 9.9 | 9.4 | 13.9 | 26.7 | 16.8 | 20.0 | 27.4 | |
| P/S | 2.6 | 2.3 | 3.8 | 3.9 | 3.2 | 2.8 | 3.6 | 4.4 | 5.5 | 5.3 | 6.2 | 8.2 | |
| P/B | 1.4 | 1.3 | 2.5 | 3.0 | 3.2 | 3.5 | 3.9 | 4.6 | 5.3 | 5.0 | 7.1 | 7.4 | |
| P / Tangible Book | 10.0 | 40.8 | 172.6 | 6.9 | 11.8 | 20.1 | · | · | · | · | · | · | |
| P / Cash Flow | 11.7 | 7.8 | 24.2 | 28.8 | 9.7 | 8.8 | 7.3 | 9.6 | 14.8 | 13.5 | 18.0 | 27.1 | |
| P / FCF | 12.6 | 8.2 | 29.5 | 34.9 | 10.4 | 9.8 | 7.9 | 11.0 | 18.3 | 15.7 | 21.8 | 30.0 | |
| Earnings Yield | 5.0% | 7.3% | 3.1% | 7.5% | 4.3% | 10.1% | 10.6% | 7.2% | 3.7% | 6.0% | 5.0% | 3.6% |
Demonstração de Resultados 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | |
| Cost of Revenue | $777M | $661M | $496M | $674M | $605M | $629M | $584M | $639M | $546M | $542M | $618M | $660M | $593M | $663M | $571M | $470M | |
| SG&A Expense | $710M | $607M | $682M | $595M | $584M | $572M | $680M | $588M | $554M | $582M | $608M | $788M | $548M | $605M | $633M | $563M | |
| Operating Expenses | $2.60B | $2.10B | $2.34B | $1.98B | $1.90B | $2.12B | $2.16B | $2.01B | $1.77B | $1.83B | $2.09B | $2.67B | $1.75B | $2.02B | $1.94B | $1.14B | |
| Interest Expense | $82M | $68M | $68M | $67M | $73M | $60M | $60M | $60M | $61M | $69M | $72M | $64M | $49M | $62M | $55M | $60M | |
| Interest Income | $25M | $38M | $37M | $32M | $32M | $24M | $18M | $12M | $20M | $17M | $24M | $96M | $76M | $81M | $50M | $24M | |
| Other Non-op | $3M | $-1M | $-37M | $16M | $2M | $2M | $8M | $-800.0K | $-2M | $-2M | $5M | $-3M | $-2M | $600.0K | $35M | $2M | |
| Pretax Income | $132M | $378M | $-56M | $557M | $744M | $311M | $292M | $451M | $699M | $465M | $292M | $-141M | $708M | $438M | $604M | $1.37B | |
| Income Tax | $35M | $58M | $-7M | $91M | $109M | $71M | $25M | $62M | $115M | $71M | $43M | $-73M | $115M | $51M | $54M | $236M | |
| Net Income | $98M | $320M | $-49M | $466M | $635M | $240M | $267M | $388M | $584M | $393M | $250M | $-68M | $592M | $388M | $550M | $1.13B | |
| EPS (Basic) | $0.66 | $2.17 | $-0.33 | $3.18 | $4.33 | $1.65 | $1.82 | $2.67 | $4.01 | $2.71 | $1.71 | $-0.47 | $4.09 | $2.69 | $3.79 | $7.86 | |
| EPS (Diluted) | $0.66 | $2.15 | $-0.35 | $3.17 | $4.33 | $1.64 | $1.82 | $2.66 | $4.00 | $2.70 | $1.70 | $-0.47 | $4.07 | $2.67 | $3.73 | $7.84 | |
| Shares (Basic) | 147,700,000 | 147,200,000 | -292,700,000 | 146,600,000 | 146,500,000 | 146,100,000 | -290,900,000 | 145,700,000 | 145,600,000 | 145,200,000 | -289,200,000 | 144,800,000 | 144,700,000 | 144,400,000 | -292,100,000 | 144,400,000 | |
| Shares (Diluted) | 148,700,000 | 148,400,000 | -293,300,000 | 147,100,000 | 146,700,000 | 146,600,000 | -292,000,000 | 146,100,000 | 145,900,000 | 145,900,000 | -289,900,000 | 144,800,000 | 145,500,000 | 145,200,000 | -292,600,000 | 144,800,000 | |
| EBITDA | · | $204M | · | · | · | $183M | · | · | · | $148M | · | · | · | $112M | · | · |
Balanço Patrimonial 28
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables | · | · | $1.34B | · | · | · | $1.40B | · | · | · | · | · | · | $1.63B | · | $1.57B | |
| Inventory | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B | $2.47B | $2.51B | $2.52B | · | $2.98B | $1.33B | $1.28B | · | $1.38B | |
| Other Current Assets | $1.24B | $1.17B | $1.12B | $917M | $851M | $757M | $752M | $674M | $615M | $1.17B | · | $974M | $896M | $1.41B | · | $1.50B | |
| Current Assets | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B | $6.83B | $7.11B | $6.76B | · | $8.45B | $10.43B | $9.76B | · | $9.77B | |
| PP&E (Net) | $2.99B | $3.02B | $3.06B | $3.08B | $3.10B | $3.13B | $3.18B | $3.21B | $3.25B | $3.28B | · | $3.30B | $3.31B | $3.30B | · | $3.27B | |
| PP&E (Gross) | · | · | $5.99B | · | · | · | $5.85B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.10B | $3.00B | $2.93B | $2.87B | $2.81B | $2.74B | $2.67B | $2.60B | $2.54B | $2.47B | · | $2.34B | $2.28B | $2.22B | · | $2.10B | |
| Goodwill | $6.99B | $6.49B | $6.49B | $6.49B | $6.49B | $6.48B | $6.48B | $6.49B | $6.23B | $6.23B | $6.22B | $6.81B | $5.75B | $5.75B | $5.75B | $5.74B | |
| Intangibles | $13.52B | $9.05B | $9.18B | $9.33B | $9.47B | $9.58B | $9.69B | $9.81B | $8.23B | $8.28B | · | $7.34B | $1.78B | $1.81B | · | $2.01B | |
| Other Non-current Assets | $832M | $778M | $751M | $730M | $638M | $559M | $560M | $631M | $682M | $698M | · | $755M | $1.10B | $1.38B | · | $1.61B | |
| Total Assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Accounts Payable | $404M | $358M | $432M | $413M | $408M | $392M | $424M | $423M | $354M | $387M | · | $440M | $445M | $491M | · | $383M | |
| Short-term Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Current Liabilities | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | $5.30B | $5.53B | $5.42B | $3.11B | $3.22B | · | $5.02B | $3.19B | $3.01B | · | $3.93B | |
| Capital Leases | $265M | $273M | $290M | $305M | $311M | $323M | $334M | $357M | $368M | $406M | · | $429M | $304M | $327M | · | $355M | |
| Deferred Tax | $946M | $484M | $508M | $358M | $118M | $133M | $190M | $882M | $591M | $658M | · | $728M | $144M | $251M | · | $329M | |
| Other Non-current Liabilities | $821M | $787M | $748M | $762M | $800M | $752M | $732M | $744M | $557M | $777M | · | $748M | $777M | $936M | · | $1.20B | |
| Total Liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B | $11.35B | · | $13.71B | $10.70B | $10.81B | · | $12.09B | |
| Long-term Debt | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | · | $4.55B | $6.29B | $6.29B | · | $6.79B | $6.28B | $6.28B | · | $6.28B | |
| Total Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Common Stock | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $983M | $897M | $863M | $798M | $714M | $630M | $569M | $488M | $408M | $330M | · | $242M | $171M | $91M | · | $0 | |
| Retained Earnings | $20.97B | $20.87B | $20.55B | $20.60B | $20.14B | $19.50B | $19.26B | $18.99B | $18.60B | $18.02B | · | $17.38B | $17.45B | $16.85B | · | $15.92B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | · | $2.98B | $2.98B | $2.98B | · | $2.98B | |
| AOCI | $-128M | $-140M | $-182M | $-215M | $-238M | $-174M | $-136M | $-146M | $-146M | $-160M | · | $-159M | $-173M | $-172M | · | $-164M | |
| Stockholders' Equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.47B | $13.80B | $13.39B | $12.78B | |
| Liabilities + Equity | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Shares Outstanding | 171,500,000 | 171,400,000 | 146,800,000 | 170,500,000 | 170,400,000 | 170,300,000 | 145,800,000 | 169,500,000 | 169,500,000 | 169,400,000 | 144,900,000 | 168,700,000 | 168,600,000 | 168,600,000 | 144,000,000 | 167,800,000 |
Fluxo de Caixa 15
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $236M | $204M | $200M | $202M | $194M | $183M | $184M | $183M | $159M | $148M | $140M | $125M | $117M | $112M | $120M | $121M | |
| Stock-based Comp | $77M | $84M | $60M | $75M | $75M | $81M | $75M | $73M | $71M | $73M | $55M | $62M | $72M | $76M | $67M | $64M | |
| Deferred Tax | $-28M | $24M | $167M | $254M | $-31M | $-28M | $-58M | $-53M | $-87M | $40M | $72M | $-207M | $-106M | $-64M | $-29M | $-92M | |
| Amort. of Intangibles | $168M | · | $132M | $136M | $127M | · | $111M | $110M | $87M | · | · | · | · | · | · | · | |
| Restructuring | $165M | $8M | $7M | $7M | $-700.0K | $35M | $5M | $7M | $7M | $12M | $99M | $76M | $34M | $10M | $7M | $15M | |
| Other Non-cash | · | $14M | · | · | · | $-218M | · | · | · | $-100M | · | · | · | $-56M | · | · | |
| Operating Cash Flow | $449M | $646M | $512M | $1.27B | $161M | $259M | $761M | $936M | $626M | $553M | $12M | $592M | $487M | $455M | $-175M | $661M | |
| CapEx | $41M | $51M | $44M | $46M | $27M | $37M | $39M | $35M | $34M | $46M | $65M | $74M | $71M | $67M | $86M | $59M | |
| Investing Cash Flow | $-3.84B | $-210M | $-1.23B | $-35M | $-57M | $-47M | $-19M | $-1.18B | $466M | $-66M | $-652M | $-1.74B | $-754M | $-953M | $-141M | $1.67B | |
| Debt Issued | · | · | $0 | $-300.0K | · | · | $0 | $0 | · | · | $0 | · | · | · | $0 | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-400M | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $250M | |
| Financing Cash Flow | $1.30B | $-44M | $-137M | $-130M | $-12M | $-23M | $8M | $-7M | $-245M | $-440M | $-646M | $849M | $-10M | $-43M | $-7M | $-1.25B | |
| Free Cash Flow | · | $594M | · | · | · | $222M | · | · | · | $507M | · | · | · | $389M | · | · | |
| Levered FCF | · | $537M | · | · | · | $176M | · | · | · | $449M | · | · | · | $333M | · | · |
Lucratividade 5
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 3.6% | 12.9% | · | 18.4% | 24.0% | 9.9% | · | 15.8% | 23.7% | 17.2% | · | -2.7% | 24.1% | 15.8% | · | 45.2% | |
| Pretax Margin | 4.8% | 15.2% | · | 22.0% | 28.1% | 12.8% | · | 18.3% | 28.3% | 20.3% | · | -5.6% | 28.8% | 17.8% | · | 54.7% | |
| EBITDA Margin | · | 8.2% | · | · | · | 7.5% | · | · | · | 6.4% | · | · | · | 4.6% | · | · | |
| ROA | 0.32% | 1.1% | · | 1.6% | 2.3% | 0.88% | · | 1.4% | 2.2% | 1.5% | · | -0.26% | 2.4% | 1.6% | · | 4.7% | |
| ROE | 0.53% | 1.8% | · | 2.7% | 3.8% | 1.5% | · | 2.5% | 3.9% | 2.7% | · | -0.50% | 4.7% | 3.0% | · | 9.8% |
Liquidez e Solvência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 3.1 | · | 2.7 | 2.5 | 1.4 | · | 1.3 | 2.3 | 2.1 | · | 1.7 | 3.3 | 3.2 | · | 2.5 | |
| Quick Ratio | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.5 | · | 0.4 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | · | · | · | 0.0 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.5 | 0.5 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | 1.5 | · | 1.5 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $10.39B | $10.09B | · | $10.08B | $10.01B | $9.65B | · | $9.75B | $9.74B | $9.74B | · | $9.96B | $10.02B | $10.09B | · | $10.41B | |
| Net Income TTM | $1.52B | $1.66B | · | $1.73B | $1.85B | $1.61B | · | $1.30B | $1.50B | $1.30B | · | $2.05B | $3.17B | $2.88B | · | $2.83B | |
| Market Cap | $37.05B | $31.42B | · | $23.88B | $21.40B | $23.30B | · | $32.86B | $39.29B | $36.53B | · | $43.36B | $48.03B | $46.88B | · | $44.80B | |
| P/E | 21.0 | 16.2 | · | 11.9 | 9.9 | 12.4 | · | 21.8 | 22.5 | 24.0 | · | 18.2 | 13.1 | 14.0 | · | 13.8 | |
| P/S | 3.6 | 3.1 | · | 2.4 | 2.1 | 2.4 | · | 3.4 | 4.0 | 3.8 | · | 4.4 | 4.8 | 4.6 | · | 4.3 | |
| P/B | 2.0 | 1.7 | · | 1.3 | 1.2 | 1.4 | · | 2.0 | 2.5 | 2.4 | · | 3.0 | 3.3 | 3.4 | · | 3.5 | |
| P / Tangible Book | · | 10.1 | · | 10.0 | 12.8 | 25.4 | · | 486.0 | 27.5 | 52.1 | · | 130.7 | 6.9 | 7.5 | · | 8.9 | |
| P / Cash Flow | · | 48.7 | · | · | · | 89.9 | · | · | · | 66.0 | · | · | · | 103.0 | · | · | |
| P / FCF | · | 52.9 | · | · | · | 104.9 | · | · | · | 72.0 | · | · | · | 120.6 | · | · | |
| Earnings Yield | 4.8% | 6.2% | · | 8.4% | 10.1% | 8.0% | · | 4.6% | 4.4% | 4.2% | · | 5.5% | 7.7% | 7.1% | · | 7.2% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Margem Operacional % | — | — | — | — | 25.9% |
| Lucro líquido | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EPS Diluído | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 |
| Índice de Liquidez Seca | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
Últimas notícias Notícias recentes mencionando esta empresa
- What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
- Biogen avança medicamento para Alzheimer para teste de estágio avançado, apesar de dados decepcionantes
- Por que a ação da Biogen foi uma vencedora na quarta-feira
- Aqui estão as principais chamadas de pesquisa de analistas de Wall Street para terça-feira: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla e muito mais
- Por que as ações da Biogen foram esmagadas na segunda-feira
- Apellis Pharma Dispara com Acordo da Biogen. É Tarde Demais para Perseguir as Ações da APLS?
- Biogen adquire Apellis Pharmaceuticals por US$ 5,6 bilhões, adicionando terapias C3 ao portfólio
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 1.147 declarantes · $23.5B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 133 (-29 vs trimestre anterior) | 76 (-23 vs trimestre anterior) | 406 (+25 vs trimestre anterior) | 295 (-2 vs trimestre anterior) | +24.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | $3.274.304.389 | 15.154.606 | 13,94% | Ações |
| VANGUARD GROUP INC | $2.812.686.259 | 15.982.080 | 11,97% | Ações |
| FMR LLC | $2.480.996.199 | 11.482.904 | 10,56% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.085.220.339 | 9.651.117 | 8,88% | Ações |
| STATE STREET CORP | $1.586.815.292 | 7.344.327 | 6,75% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.427.062.472 | 6.604.936 | 6,07% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $853.425.885 | 3.965.587 | 3,63% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $651.741.965 | 3.016.486 | 2,77% | Ações |
| NORGES BANK | $557.441.930 | 2.580.033 | 2,37% | Ações |
| Boston Partners | $237.039.714 | 1.097.693 | 1,01% | Ações |
| Alyeska Investment Group, L.P. | $201.448.726 | 932.374 | 0,86% | Ações |
| Pictet Asset Management Holding SA | $184.144.886 | 851.819 | 0,78% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $183.196.029 | 847.893 | 0,78% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $179.182.447 | 829.318 | 0,76% | Ações |
| Robeco Institutional Asset Management B.V. | $170.923.341 | 791.092 | 0,73% | Ações |
| FRED ALGER MANAGEMENT, LLC | $170.321.610 | 788.307 | 0,73% | Ações |
| BANK OF AMERICA CORP /DE/ | $156.665.322 | 725.101 | 0,67% | Ações |
| Employees Provident Fund Board | $152.148.588 | 704.196 | 0,65% | Ações |
| FIRST TRUST ADVISORS LP | $147.357.277 | 682.021 | 0,63% | Ações |
| AustralianSuper Pty Ltd | $145.348.531 | 672.723 | 0,62% | Ações |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $129.114.863 | 597.588 | 0,55% | Ações |
| BlackRock, Inc. | $124.065.973 | 574.220 | 0,53% | Ações |
| Artemis Investment Management LLP | $123.364.642 | 570.974 | 0,53% | Ações |
| Legal & General Group Plc | $119.267.279 | 552.010 | 0,51% | Ações |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $116.672.616 | 540.001 | 0,50% | Ações |
| Caisse de depot et placement du Quebec | $110.232.516 | 510.194 | 0,47% | Ações |
| UBS Group AG | $108.289.272 | 501.200 | 0,46% | Opção de compra |
| CITADEL ADVISORS LLC | $90.389.997 | 418.356 | 0,38% | Ações |
| Swiss National Bank | $89.427.234 | 413.900 | 0,38% | Ações |
| National Pension Service | $87.734.188 | 406.064 | 0,37% | Ações |
| LMR Partners LLP | $84.047.340 | 389.000 | 0,36% | Opção de compra |
| BNP PARIBAS FINANCIAL MARKETS | $83.732.325 | 387.542 | 0,36% | Ações |
| Candriam S.C.A. | $82.957.583 | 384.326 | 0,35% | Ações |
| ROYAL BANK OF CANADA | $78.304.000 | 362.418 | 0,33% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $77.527.297 | 358.823 | 0,33% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $74.890.069 | 346.617 | 0,32% | Ações |
| VICTORY CAPITAL MANAGEMENT INC | $74.199.109 | 343.419 | 0,32% | Ações |
| Fisher Asset Management, LLC | $73.032.374 | 338.018 | 0,31% | Ações |
| Vanguard Global Advisers, LLC | $72.582.332 | 335.936 | 0,31% | Ações |
| California Public Employees Retirement System | $71.106.642 | 329.106 | 0,30% | Ações |
| Swedbank AB | $69.271.861 | 320.614 | 0,29% | Ações |
| CITADEL ADVISORS LLC | $68.058.900 | 315.000 | 0,29% | Opção de compra |
| GOLDMAN SACHS GROUP INC | $63.917.486 | 295.832 | 0,27% | Ações |
| LMR Partners LLP | $62.268.492 | 288.200 | 0,27% | Opção de venda |
| VANGUARD ASSET MANAGEMENT, Ltd | $61.442.279 | 284.376 | 0,26% | Ações |
| Patient Capital Management, LLC | $61.295.674 | 283.697 | 0,26% | Ações |
| Gotham Asset Management, LLC | $60.475.194 | 279.900 | 0,26% | Ações |
| CAUSEWAY CAPITAL MANAGEMENT LLC | $60.125.780 | 278.283 | 0,26% | Ações |
| PERCEPTIVE ADVISORS LLC | $59.669.938 | 276.173 | 0,25% | Ações |
| Balyasny Asset Management L.P. | $57.275.345 | 265.090 | 0,24% | Ações |
| RHUMBLINE ADVISERS | $56.819.153 | 262.979 | 0,24% | Ações |
| HSBC HOLDINGS PLC | $52.886.951 | 244.779 | 0,23% | Ações |
| AEGON ASSET MANAGEMENT UK Plc | $52.092.282 | 241.101 | 0,22% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47.304.392 | 218.941 | 0,20% | Ações |
| JANE STREET GROUP, LLC | $47.122.686 | 218.100 | 0,20% | Opção de venda |
| KLP KAPITALFORVALTNING AS | $43.034.183 | 199.177 | 0,18% | Ações |
| JANE STREET GROUP, LLC | $41.289.066 | 191.100 | 0,18% | Opção de compra |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $40.458.548 | 220.687 | 0,17% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $40.387.880 | 186.929 | 0,17% | Ações |
| NISSAY ASSET MANAGEMENT CORP /JAPAN | $40.036.134 | 185.301 | 0,17% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $39.509.594 | 182.864 | 0,17% | Ações |
| ALLIANCEBERNSTEIN L.P. | $39.411.367 | 214.975 | 0,17% | Ações |
| BARCLAYS PLC | $38.890.800 | 180.000 | 0,17% | Opção de venda |
| BARCLAYS PLC | $37.038.518 | 171.427 | 0,16% | Ações |
| Quantinno Capital Management LP | $32.836.341 | 151.977 | 0,14% | Ações |
| MORGAN STANLEY | $32.548.902 | 150.647 | 0,14% | Ações |
| LETKO, BROSSEAU & ASSOCIATES INC | $31.666.186 | 146.562 | 0,13% | Ações |
| Portolan Capital Management, LLC | $30.865.467 | 142.856 | 0,13% | Ações |
| Palo Alto Investors LP | $30.308.681 | 140.279 | 0,13% | Ações |
| Walleye Trading LLC | $30.087.003 | 139.253 | 0,13% | Ações |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $29.872.456 | 138.260 | 0,13% | Ações |
| Nippon Life Global Investors Americas, Inc. | $29.647.753 | 137.220 | 0,13% | Ações |
| CITADEL ADVISORS LLC | $28.995.252 | 134.200 | 0,12% | Opção de venda |
| IEQ CAPITAL, LLC | $28.550.680 | 132.142 | 0,12% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28.001.160 | 129.599 | 0,12% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $26.210.455 | 121.311 | 0,11% | Ações |
| AMERICAN CENTURY COMPANIES INC | $24.663.681 | 114.152 | 0,10% | Ações |
| Woodline Partners LP | $24.298.756 | 112.463 | 0,10% | Ações |
| AVIVA PLC | $23.345.715 | 108.052 | 0,10% | Ações |
| Eurizon Capital SGR S.p.A. | $22.171.682 | 102.594 | 0,09% | Ações |
| ADAMS DIVERSIFIED EQUITY FUND, INC. | $21.670.818 | 100.300 | 0,09% | Ações |
| NEW YORK STATE COMMON RETIREMENT FUND | $21.637.329 | 100.145 | 0,09% | Ações |
| UBS Group AG | $21.607.945 | 100.009 | 0,09% | Ações |
| SPHERA FUNDS MANAGEMENT LTD. | $21.606.000 | 100.000 | 0,09% | Opção de compra |
| Balyasny Asset Management L.P. | $21.606.000 | 100.000 | 0,09% | Opção de compra |
| Integral Health Asset Management, LLC | $21.606.000 | 100.000 | 0,09% | Ações |
| Illinois Municipal Retirement Fund | $21.455.406 | 99.303 | 0,09% | Ações |
| Susquehanna Portfolio Strategies, LLC | $21.346.944 | 98.801 | 0,09% | Ações |
| APG Asset Management N.V. | $20.973.675 | 110.984 | 0,09% | Ações |
| SPHERA FUNDS MANAGEMENT LTD. | $20.877.014 | 96.626 | 0,09% | Ações |
| LPL Financial LLC | $20.626.314 | 95.466 | 0,09% | Ações |
| Rhenman & Partners Asset Management AB | $20.493.291 | 94.850 | 0,09% | Ações |
| PEAK6 LLC | $20.374.458 | 94.300 | 0,09% | Opção de compra |
| STRS OHIO | $20.265.132 | 93.794 | 0,09% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $19.614.791 | 90.784 | 0,08% | Ações |
| Hudson Bay Capital Management LP | $19.445.400 | 90.000 | 0,08% | Ações |
| VAN ECK ASSOCIATES CORP | $19.191.313 | 88.824 | 0,08% | Ações |
| Point72 Asset Management, L.P. | $19.045.473 | 88.149 | 0,08% | Ações |
| ANTIPODES PARTNERS Ltd | $18.759.842 | 86.827 | 0,08% | Ações |
| MACKENZIE FINANCIAL CORP | $18.666.288 | 86.394 | 0,08% | Ações |
Executivos da empresa 83 insiders · 51 diretores · 28 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Christopher Viehbacher | President and CEO | 13 de Fevereiro de 2026 A | 29.924 | 0 | 0 | $0 |
| Michel Vounatsos | Chief Executive Officer | 18 de Fevereiro de 2022 J | 67.261 | 0 | 0 | $0 |
| George A Scangos | Chief Executive Officer | 21 de Julho de 2016 S | 54.779 | 0 | 0 | $0 |
| MULLEN JAMES C | CEO & President | 8 de Junho de 2010 A | 95.503 | 0 | 0 | $0 |
| Robin Kramer | Chief Financial Officer | 13 de Fevereiro de 2026 A | 11.472 | 0 | 0 | $0 |
| Michael R. Mcdonnell | EVP, Chief Financial Officer | 10 de Fevereiro de 2025 M | 24.341 | 0 | 0 | $0 |
| Jeffrey D Capello | EVP & Chief Financial Officer | 12 de Fevereiro de 2020 J | 3.118 | 0 | 0 | $0 |
| Paul J Clancy | Executive VP and CFO | 25 de Abril de 2017 S | 10.813 | 0 | 0 | $0 |
| KELLOGG PETER N | EVP, Finance and CFO | 20 de Março de 2007 S | 18.966 | 0 | 0 | $0 |
| Robert A Hamm | Chief Operating Officer | 23 de Abril de 2010 S | 27.212 | 0 | 0 | $0 |
| HASLER HANS PETER | Chief Operating Officer | 24 de Fevereiro de 2009 A | 53.261 | 0 | 0 | $0 |
| William R Rohn | Chief Operating Officer | 17 de Novembro de 2004 M | 65.462 | 0 | 0 | $0 |
| Adam Keeney | Head of Corporate Development | 1 de Maio de 2026 M | 6.365 | 0 | 0 | $0 |
| Sean Godbout | Chief Accounting Officer | 1 de Abril de 2026 M | 1.342 | 0 | 0 | $0 |
| Jane Grogan | Head of Research | 13 de Fevereiro de 2026 A | 4.058 | 0 | 0 | $0 |
| Nicole Murphy | Head of Pharm Ops and Tech | 13 de Fevereiro de 2026 A | 19.611 | 1 | 0 | $585 |
| Rachid Izzar | Head of Global Product Strat. | 13 de Fevereiro de 2026 A | 11.011 | 0 | 0 | $0 |
| Singhal Priya | Head of Development | 13 de Fevereiro de 2026 A | 8.043 | 0 | 3 | $-734.709 |
| Ginger Gregory | EVP, Human Resources | 13 de Fevereiro de 2026 A | 22.359 | 0 | 0 | $0 |
| Susan H Alexander | EVP Chief Legal Officer | 13 de Fevereiro de 2026 A | 41.807 | 0 | 0 | $0 |
| Chirfi Guindo | Head of Glob Prod Strat & Com | 18 de Fevereiro de 2022 J | 7.364 | 0 | 0 | $0 |
| Alphonse Galdes | EVP Pharmaceutical Oper & Tech | 19 de Janeiro de 2022 A | 5.064 | 0 | 0 | $0 |
| Alfred Sandrock | Head of Research & Development | 7 de Junho de 2021 S | 10.169 | 0 | 0 | $0 |
| Daniel Karp | EVP, Corporate Development | 12 de Fevereiro de 2020 A | 930 | 0 | 0 | $0 |
| Michael D Ehlers | EVP, Research and Development | 1 de Junho de 2019 J | 8.025 | 0 | 0 | $0 |
| Paul Mckenzie | EVP Pharmaceutical Oper & Tech | 1 de Março de 2019 J | 7.235 | 0 | 0 | $0 |
| Gregory F Covino | VP, Chief Accounting Officer | 1 de Março de 2018 A | 4.744 | 0 | 0 | $0 |
| Jean-Paul Kress | EVP Pres Int'l & Global Hd GTO | 3 de Julho de 2017 A | — | 0 | 0 | $0 |
| Adriana Karaboutis | EVP, Tech, Bus. Sol & Corp Aff | 28 de Fevereiro de 2017 M | 8.752 | 0 | 0 | $0 |
| Kenneth Dipietro | EVP Human Resources | 28 de Fevereiro de 2017 J | 7.177 | 0 | 0 | $0 |
| Adam Koppel | EVP, Strategy and Bus. Dev. | 6 de Junho de 2016 S | 2.402 | 0 | 0 | $0 |
| Spyridon Artavanis-Tsakonas | EVP, Chief Scientific Officer | 2 de Abril de 2016 M | 3.150 | 0 | 0 | $0 |
| John Cox | EVP Pharmaceutical Oper & Tech | 1 de Abril de 2016 A | 39.045 | 0 | 0 | $0 |
| Steven H Holtzman | EVP Corporate Development | 23 de Fevereiro de 2016 J | 8.326 | 0 | 0 | $0 |
| Douglas E Williams | EVP Research & Development | 19 de Junho de 2015 S | 11.817 | 0 | 0 | $0 |
| Stuart A Kingsley | EVP, Global Comm. Operations | 23 de Fevereiro de 2015 A | 8.132 | 0 | 0 | $0 |
| Raymond Pawlicki | SVP, Chief Information Officer | 22 de Novembro de 2013 M | 8.710 | 0 | 0 | $0 |
| Robert E. Gagnon | Vice President, Finance | 29 de Fevereiro de 2012 S | 3.999 | 0 | 0 | $0 |
| Francesco Granata | EVP Global Commercial Operatio | 1 de Fevereiro de 2012 M | 3.529 | 0 | 0 | $0 |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 1 de Março de 2011 M | 10.201 | 0 | 0 | $0 |
| Michael F Maclean | SVP, Chief Accounting Officer | 1 de Outubro de 2010 F | 10.681 | 0 | 0 | $0 |
| Michael Lytton | EVP Corporate & Business Devel | 2 de Março de 2010 F | 18.869 | 0 | 0 | $0 |
| Mark C Wiggins | EVP Corp. and Bus. Dev. | 26 de Setembro de 2008 S | 22.780 | 0 | 0 | $0 |
| Faheem Hasnain | EVP, Oncology/Rheumatology SBU | 9 de Julho de 2008 M | 25.454 | 0 | 0 | $0 |
| ADELMAN BURT A | EVP, Portfolio Strategy | 15 de Outubro de 2007 M | 12.769 | 0 | 0 | $0 |
| Michael Kowolenko | SVP, Pharm Ops & Technology | 25 de Julho de 2007 M | 18.124 | 0 | 0 | $0 |
| Connie Matsui | EVP, Corp. Strategy and Comm. | 12 de Fevereiro de 2007 A | 22.837 | 0 | 0 | $0 |
| William H Rastetter | Executive Chairman | 23 de Fevereiro de 2005 J | 373.929 | 0 | 0 | $0 |
| Michael Gilman | EVP - Research | 17 de Fevereiro de 2005 A | 23.000 | 0 | 0 | $0 |
| BUCKNUM THOMAS J | EVP and General Counsel | 17 de Fevereiro de 2005 A | 5.750 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 7 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Biogen Inc. ×8 declarações | 14 de Maio de 2026 | 0,00% | Emenda | M&A / venda | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn ×4 declarações | 22 de Junho de 2011 | — | Declaração inicial | — | SEC |
| 22 de Março de 2010 | — | Declaração inicial | — | SEC | |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 28 de Janeiro de 2010 | — | Declaração inicial | — | SEC |
| AND | 8 de Maio de 2008 | — | Declaração inicial | — | SEC |
| Biogen Idec Inc., Biogen Idec MA Inc. ×3 declarações | 9 de Novembro de 2006 | — | Declaração inicial | M&A / venda | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada | 14 de Fevereiro de 2001 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 199 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 4,72% | 82.332 SH | 8 de Agosto de 2026 | Diário |
| IBRN · iShares Trust | 4,02% | 1.505 SH | 8 de Agosto de 2026 | Diário |
| PJP · Invesco Exchange-Traded Fund Trust | 2,74% | 66.627 SH | 8 de Agosto de 2026 | Diário |
| IBB · iShares Trust | 2,33% | 1.074.761 SH | 8 de Agosto de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 2,23% | 103.216 NS | 30 de Abril de 2026 | N-PORT |
| SPIT · RBB Fund, Inc. | 2,11% | 3.185 NS | 30 de Abril de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 2,09% | 8.035 SH | 8 de Agosto de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,73% | 5.434 NS | 30 de Abril de 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,62% | 61.078 SH | 8 de Agosto de 2026 | Diário |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 1,48% | 84.204 SH | 8 de Agosto de 2026 | Diário |
| BIB · ProShares Trust | 1,44% | 5.425 NS | 31 de Maio de 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 1,39% | 2.280 NS | 31 de Maio de 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 1,34% | 2.744 NS | 30 de Abril de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1,30% | 764 NS | 30 de Abril de 2026 | N-PORT |
| NUMV · Nushares ETF Trust | 1,01% | 23.096 NS | 30 de Abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,93% | 25.484 NS | 30 de Abril de 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,88% | 5.573 SH | 8 de Agosto de 2026 | Diário |
| ABCS · EA Series Trust | 0,75% | 431 NS | 29 de Maio de 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,74% | 6.263 NS | 30 de Abril de 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0,73% | 10.857 NS | 30 de Abril de 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,72% | 49.392 NS | 30 de Abril de 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,70% | 22.249 NS | 31 de Maio de 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 558 NS | 30 de Abril de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,67% | 642.650 NS | 30 de Abril de 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,66% | 1.636 NS | 30 de Abril de 2026 | N-PORT |
| ITAN · EA Series Trust | 0,59% | 2.701 NS | 29 de Maio de 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,58% | 18.519 NS | 30 de Abril de 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,55% | 948.376 SH | 8 de Agosto de 2026 | Diário |
| IYH · iShares Trust | 0,50% | 88.325 SH | 8 de Agosto de 2026 | Diário |
| RCGE · EA Series Trust | 0,48% | 2.389 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,47% | 441.144 SH | 8 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,45% | 67.622 NS | 30 de Abril de 2026 | N-PORT |
| RPV · Invesco Exchange-Traded Fund Trust | 0,43% | 35.530 SH | 8 de Agosto de 2026 | Diário |
| IMCV · iShares Trust | 0,42% | 23.383 SH | 8 de Agosto de 2026 | Diário |
| RXL · ProShares Trust | 0,42% | 1.530 NS | 31 de Maio de 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,40% | 2.927 NS | 30 de Abril de 2026 | N-PORT |
| IXJ · iShares Trust | 0,38% | 77.453 SH | 8 de Agosto de 2026 | Diário |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,37% | 10.761.000 | 8 de Agosto de 2026 | Diário |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,36% | 2.605 NS | 30 de Abril de 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,35% | 7.256 NS | 31 de Maio de 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,34% | 26.804 NS | 30 de Abril de 2026 | N-PORT |
| VLUE · iShares Trust | 0,33% | 149.494 SH | 8 de Agosto de 2026 | Diário |
| VO · VANGUARD INDEX FUNDS | 0,31% | 3.199.564 SH | 8 de Agosto de 2026 | Diário |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,29% | 6.727 NS | 30 de Abril de 2026 | N-PORT |
| IWS · iShares Trust | 0,29% | 222.364 SH | 8 de Agosto de 2026 | Diário |
| GINN · Goldman Sachs ETF Trust | 0,27% | 2.960 NS | 31 de Maio de 2026 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0,27% | 1.332 NS | 31 de Maio de 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0,26% | 8.169 NS | 31 de Maio de 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 8.407 SH | 8 de Agosto de 2026 | Diário |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,26% | 136 NS | 31 de Maio de 2026 | N-PORT |